Oxford Global Immuno 2024
Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is attending Oxford Global’s Immuno 2024 Event in London on 25th and 26th of April 2024.
Physiomics’ Head of Business Development, Hayley Close will be attending the event which brings together over 400 experts in the field of immuno-oncology to discuss the latest advancements in the discovery & development of cancer immunotherapies. Physiomics will be looking to engage with pharma and biotech leaders developing cancer immunotherapies to identify opportunities where PKPD and QSP modelling techniques can help inform development of the next generation of IO drugs.
If you are interested in meeting at the Immuno 2024 event, please contact Hayley directly at hclose@physiomics.co.uk.
We look forward to seeing you there!
Enquiries:
Physiomics plc
Dr Jim Millen, Non-Executive Chairman, +44 (0)1865 784 980
Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.